Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Asset Acquisition [Table] Asset Acquisition [Table] Statistical Measurement [Domain] Statistical Measurement [Domain] Title of 12(b) Security Title of 12(b) Security Subsequent Event Subsequent Event [Member] Document Fiscal Year Focus Document Fiscal Year Focus Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Adjustment to Compensation, Amount Adjustment to Compensation Amount Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Segment Reporting [Abstract] Marvelon/Mercilon Marvelon/Mercilon [Member] Marvelon/Mercilon Restructuring Plan [Axis] Restructuring Plan [Axis] Common stock, $0.01 par value Authorized - 500,000 Issued and outstanding - 262,609 in 2026 and 260,316 in 2025 Common Stock, Value, Issued Employee withholding taxes related to stock-based awards Payment, Tax Withholding, Share-Based Payment Arrangement Interest expense Interest Expense, Operating and Nonoperating Revenue from External Customers by Products and Services [Table] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Table] Schedule of Long-term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Average maturity of long-term debt Debt Instrument, Average Maturity Debt Instrument, Average Maturity Debt prepayment period prior to closing Debt Instrument, Debt Covenants, Debt Prepayment Period, Prior To Closing Debt Instrument, Debt Covenants, Debt Prepayment Period, Prior To Closing Restatement Determination Date Restatement Determination Date Restricted Stock, Remaining Term Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest, Outstanding, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest, Outstanding, Weighted Average Remaining Contractual Term Derivative Instrument [Axis] Derivative Instrument [Axis] Fixed payment Collaborative Arrangement, Amended Future Payments Collaborative Arrangement, Amended Future Payments Proceeds from sale of Jada Proceeds from Divestiture of Businesses Stock Options, Weighted Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Dermavant acquisition, net of cash acquired Other Payments to Acquire Businesses Amendment Flag Amendment Flag Revenue Interest Purchase and Sale Agreement Revenue Interest Purchase and Sale Agreement and NovaQuest Debt [Member] Revenue Interest Purchase and Sale Agreement and NovaQuest Debt Current Liabilities: Liabilities, Current [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Disposal Group Classification [Axis] Disposal Group Classification [Axis] Inventories classified in other assets Other assets Inventory, Noncurrent Loss Contingencies [Table] Loss Contingencies [Table] Amortization Amortization Vtama Vtama [Member] Vtama Loss contingency, patents under review Loss Contingency, Patents Under Review Loss Contingency, Patents Under Review Third-Party Arrangements Related Party Transactions Disclosure [Text Block] Minimum percentage of attorneys’ eligible clients to release the company and merck of any liability related to their filed claims Minimum Percentage Of Attorneys’ Eligible Clients To Release Any Liability Related To Their Filed Claims Minimum Percentage Of Attorneys’ Eligible Clients To Release Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Brenzys Brenzys [Member] Brenzys Entity Address, State or Province Entity Address, State or Province Number of plaintiffs Loss Contingency, Number of Plaintiffs Granted/Issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Number of medicines and products Number Of Medicines And Products Number Of Medicines And Products Cumulative translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent PEO Total Compensation Amount PEO Total Compensation Amount Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Other Other Sundry Products [Member] Other Sundry Products Asset Acquisition [Axis] Asset Acquisition [Axis] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Notional amount Derivative, Notional Amount Basic (in shares) Basic weighted average number of shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Implanon Implanon [Member] Implanon Schedule of Related Party Transactions Schedule of Related Party Transactions [Table Text Block] Schedule of Equity Awards Outstanding Share-Based Payment Arrangement, Activity [Table Text Block] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Schedule of Inventory, Noncurrent Schedule of Inventory, Noncurrent [Table Text Block] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Total Current Liabilities Liabilities, Current 2.875% Senior Secured Notes Due 2028 2.875% Senior Secured Notes Due 2028 [Member] 2.875% Senior Secured Notes Due 2028 Propecia Propecia [Member] Propecia Entity Address, City or Town Entity Address, City or Town Granted/Issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Statement of Financial Position [Abstract] Potential earnout payments Discontinued Operation, Contingent Consideration Receivable Discontinued Operation, Contingent Consideration Receivable Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Fair value hedge assets Fair Value Hedge Assets Vested/Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Basis of Accounting Basis of Accounting, Policy [Policy Text Block] Thereafter Long-Term Debt, Maturity, After Year Four Long-Term Debt, Maturity, After Year Four Intangibles, net Intangible Asset, Finite-Lived, after Accumulated Amortization Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Dermavant Sciences Ltd Dermavant Sciences Ltd [Member] Dermavant Sciences Ltd Accounts receivables factored Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Recognized as: Inventory, Net [Abstract] Acquired in-process research and development and milestones Acquired in-process research and development and milestones Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Cost Capitalized Level 2 Fair Value, Inputs, Level 2 [Member] Clarinex Clarinex [Member] Clarinex Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Other Biosimilars Other Biosimilars [Member] Other Biosimilars Inventory Disposal Group, Including Discontinued Operation, Inventory, Current Samsung Bioepis Samsung Bioepis Co., Ltd. [Member] Samsung Bioepis Co., Ltd. Other comprehensive income (loss) Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Follistim AQ Follistim AQ [Member] Follistim AQ U.S. United States UNITED STATES Subsequent Event Type [Axis] Subsequent Event Type [Axis] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Cozaar/Hyzaar Cozaar/Hyzaar [Member] Cozaar/Hyzaar Payment towards amount in connection with license agreement Payment Towards Amount In Connection With License Agreement Payment Towards Amount In Connection With License Agreement Class of Treasury Stock [Table] Class of Treasury Stock [Table] Recently Issued Accounting Standards Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Litigation Case [Axis] Litigation Case [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] Related Party [Axis] Related and Nonrelated Parties [Axis] Other comprehensive income (loss), net of taxes Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Potential milestone payments Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Total principal long-term debt and short-term borrowings Long-Term Debt Contingent consideration Disposal Group, Contingent Consideration, Asset, Current Disposal Group, Contingent Consideration, Asset, Current Income taxes payable Increase (Decrease) in Income Taxes Payable Document Period End Date Document Period End Date Net changes in assets and liabilities, net of assets acquired Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Forfeited/Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Net Cash Flows Provided by (Used) in Investing Activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Liabilities held for sale Liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities, Current Face amount of debt Debt Instrument, Face Amount Additional Restructuring Initaitives Additional Restructuring Initaitives [Member] Additional Restructuring Initaitives Earnings per share: EPS: Earnings Per Share, Basic [Abstract] Security Exchange Name Security Exchange Name Contingent Consideration Acquired Contingent Consideration Acquired [Member] Contingent Consideration Acquired Granted/Issued (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Expected price of acquisition Business Combination, Price of Acquisition, Expected Northern District of Ohio Northern District of Ohio [Member] Northern District of Ohio Tax Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Increase (Decrease) to last in, first out (“LIFO”) costs Inventory, LIFO Reserve Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Statement of Comprehensive Income [Abstract] Earnings per Share (“EPS”) Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Earnings Per Share [Abstract] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items] Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Schedule of Sales of Company's Products Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Table Text Block] Total Liabilities Liabilities Trading Symbol Trading Symbol Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Geographical [Domain] Geographical [Domain] Capital expenditures Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Income taxes payable Accrued Income Taxes, Current Company Selected Measure Name Company Selected Measure Name Income Tax Disclosure [Abstract] Derivate fixed interest rate Derivative, Fixed Interest Rate Business Combination, Contingent Consideration, Type [Axis] Business Combination, Contingent Consideration, Type [Axis] Diprospan Diprospan [Member] Diprospan 7.875% notes due 2034 7.875% Notes Due 2034 [Member] 7.875% Notes Due 2034 Latin America, Middle East, Russia, and Africa Latin America, Middle East, Russia And Africa [Member] Latin America, Middle East, Russia And Africa Payables in relation to license agreement, first installment Collaborative Arrangement, Rights and Obligations, First Installment Payment Collaborative Arrangement, Rights and Obligations, First Installment Payment Collaborative arrangement, amended future payment term (in years) Collaborative Arrangement, Future Payment Term Collaborative Arrangement, Future PaymentTerm Collaboration agreement period Collaboration Arrangement, Agreement Period Collaboration Arrangement, Agreement Period Number of unfiled claims Loss Contingency, Unfiled Claims, Number Loss Contingency, Unfiled Claims, Number Employee Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Contingent consideration Contingent Consideration Liability [Member] Contingent Consideration Liability Long-term debt Long-Term Debt, Gross Related Party Transactions [Abstract] Cash Flows from Operating Activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Shanghai Henlius Biotech, Inc. Shanghai Henlius Biotech, Inc. [Member] Shanghai Henlius Biotech, Inc. Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Diluted (in shares) Diluted weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Cross-currency swap Cross-currency swaps (loss) gain Cross Currency Interest Rate Contract [Member] Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Disposal Group Name [Domain] Disposal Group Name [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Details of Asset and Liabilities Held For Sale Disposal Groups, Including Discontinued Operations [Table Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Other Women's Health Other Womens Health [Member] Other Womens Health Gross profit Gross Profit Revenue from Contract with Customer [Abstract] Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Award Timing Predetermined Award Timing Predetermined [Flag] Severance & severance related costs Severance Costs Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-based compensation plans and other APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Organization, Consolidation and Presentation of Financial Statements [Abstract] Stock awards and equity units (share equivalent) (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Inventory, Current [Table] Inventory, Current [Table] All Executive Categories All Executive Categories [Member] Legal Entity Type of Counterparty [Domain] Legal Entity Type of Counterparty [Domain] Term Loan B Facility Term Loan B Facility [Member] Term Loan B Facility Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Other Comprehensive (Loss) Income, Net of Taxes: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Long-term debt Long-Term Debt, Fair Value Depreciation Depreciation Antidilutive Securities [Axis] Antidilutive Securities [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Other Cardiovascular Other Cardiovascular [Member] Other Cardiovascular Schedule of Basic and Diluted Earnings Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Debt Disclosure [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Product and Geographic Information Segment Reporting [Text Block] Minimum Minimum [Member] Nasonex Nasonex [Member] Nasonex Expiration Date Trading Arrangement Expiration Date 2030 Long-Term Debt, Maturity, Year Four Effect of Exchange Rate Changes on Cash and Cash Equivalents Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement Location [Axis] Location, Statement of Income, Balance [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Number of manufacturing facilities Number of Manufacturing Facilities Number of Manufacturing Facilities Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Forfeited/Cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value Related Party Affiliated Entity [Member] Disposal Group, Including Discontinued Operations [Line Items] Disposal Group, Including Discontinued Operations [Line Items] Business Combination [Line Items] Business Combination [Line Items] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Common stock, authorized (in shares) Common Stock, Shares Authorized Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Amortize the asset useful life (in years) Intangible Asset, Finite-Lived, Useful Life Stock Options, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Hadlima Hadlima [Member] Hadlima Fair value adjustment Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment Schedule of Carrying Values and Estimated Fair Values of Debt Instruments Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Exercise Price Award Exercise Price Restructuring Cost [Table] Restructuring Cost [Table] Cash Flows from Investing Activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Pennsylvania State Court Pennsylvania State Court [Member] Pennsylvania State Court Amount of unrecognized compensation costs Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Quarterly Report Document Quarterly Report Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Long-Term Debt and Short-Term Borrowings Debt Disclosure [Text Block] Interest payable Interest Payable Repayments of debt Repayments of long-term debt Repayments of Long-Term Debt Disposal Group Classification [Domain] Disposal Group Classification [Domain] Other (discounts and debt issuance costs) Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Restricted Stock, Aggregate Intrinsic Value Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Aggregate Intrinsic Value Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Aggregate Intrinsic Value Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Beginning balance Ending balance Restructuring Reserve Business Combination [Table] Business Combination [Table] Acquisitions and Licensing Arrangements Mergers, Acquisitions and Dispositions Disclosures [Text Block] Equity Component [Domain] Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Measurement Input Type [Domain] Measurement Input Type [Domain] Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Singulair Singulair [Member] Singulair Adoption Date Trading Arrangement Adoption Date Consideration Disposal Group, Including Discontinued Operation, Consideration Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Counterparty Name [Domain] Counterparty Name [Domain] Cash dividends declared on common stock Dividends, Common Stock, Cash Total Stockholders’ Equity Beginning balance Ending balance Equity, Attributable to Parent Number of employees transferred Number Of Employees Transferred Number Of Employees Transferred Intangible assets, net Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent Assets Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 4.125% secured notes due 2028 4.125% Senior Secured Notes Due 2028 [Member] 4.125% Senior Secured Notes Due 2028 Insider Trading Policies and Procedures [Line Items] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] PSUs Performance Shares [Member] Equity Awards Vested and Expected to Vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract] Accretion and changes in fair value in Other expense (income), net Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Accretion Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Accretion Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Deferred income tax expense (benefit) Deferred Income Tax Expense (Benefit) Selling, general and administrative Selling, general and administrative Selling, General and Administrative Expense Noncurrent liabilities held for sale Noncurrent liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent Femur Fracture MDL Court Femur Fracture MDL Court [Member] Femur Fracture MDL Court Vested/Exercised (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Business Combination [Domain] Business Combination [Domain] Nexplanon Nexplanon [Member] Nexplanon Forfeited/Cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Oss Biotech Site Oss Biotech Site [Member] Oss Biotech Site Amount of legal defense reserves Estimated Litigation Liability Anti-dilutive shares excluded from the calculation of EPS (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of matters involved Loss Contingency, Matters Involved, Number Loss Contingency, Matters Involved, Number Entity Central Index Key Entity Central Index Key Renflexis and Brenzys Renflexis and Brenzys [Member] Renflexis and Brenzys Additional paid-in capital Additional Paid in Capital, Common Stock All Adjustments to Compensation All Adjustments to Compensation [Member] Other Other Sundry Established Brands [Member] Other Sundry Established Brands Business Combination [Axis] Business Combination [Axis] Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net Cash Flows Provided by Operating Activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation 2026 Long-Term Debt, Maturity, Remainder of Fiscal Year Organon & Co. Stockholders’ Equity: Equity, Attributable to Parent [Abstract] Income Statement [Abstract] Document Transition Report Document Transition Report Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] Mandatory payments Debt Instrument, Periodic Payment Asia Pacific and Japan Asia Pacific and Japan [Member] Asia Pacific and Japan Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Schedule of Stock Option Valuation Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Fosamax Fosamax [Member] Fosamax Remaining principal amount Debt Instrument Remaining Principal Amount Debt Instrument Remaining Principal Amount Spread on variable rate Debt Instrument, Basis Spread on Variable Rate Stock Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Estimated number of positions to be eliminated, percent Restructuring And Related Cost, Estimated Number Of Positions To Be Eliminated, Percent Restructuring And Related Cost, Estimated Number Of Positions To Be Eliminated, Percent Payables in relation to license agreement Collaborative Arrangement, Rights and Obligations, Aggregate Total Payments Collaborative Arrangement, Rights and Obligations, Aggregate Total Payments City Area Code City Area Code RSUs Restricted Stock [Member] Accumulated Other Comprehensive (Loss) Income Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Schedule of Consolidated Revenues by Geographic Area Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue [Table Text Block] Dividend payments Payments of Dividends Name Forgone Recovery, Individual Name Amount of unrecognized compensation costs period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Disposal Group, Not Discontinued Operations Disposal Group, Not Discontinued Operations [Member] Statement [Line Items] Statement [Line Items] Total Assets Assets Remaining Inventory Remaining Inventory [Member] Remaining Inventory Granted/Issued (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Benefit plan net gain and prior service credit, net of amortization Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Goodwill Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent Schedule of Stock-based Compensation Expenses Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Accrued and other current liabilities Accrued And Other Liabilities, Current Accrued And Other Liabilities, Current Stock-Based Compensation Plans Share-Based Payment Arrangement [Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Background and Nature of Operations Nature of Operations [Text Block] PEO PEO [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding 2028 Long-Term Debt, Maturity, Year Two Stock-based compensation expense Share-Based Payment Arrangement, Expense Other noncurrent liabilities Other Liabilities, Noncurrent Goodwill Goodwill California State Court California State Court [Member] California State Court Inventories Business Combination, Recognized Asset Acquired, Inventory, Current Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Vested/Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Granted/Issued (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event Type [Domain] Subsequent Event Type [Domain] Retained Earnings Retained Earnings [Member] Weighted-average interest rate of debt Long-Term Debt, Weighted Average Interest Rate, over Time Forfeited/Cancelled (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock, outstanding (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Cumulative Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Diluted (in dollars per share) Earnings Per Share, Diluted Entity Current Reporting Status Entity Current Reporting Status Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Net Cash Flows Used in Financing Activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Natco Pharma Limited Natco Pharma Limited [Member] Natco Pharma Limited Litigation Case [Domain] Litigation Case [Domain] Adjustments to reconcile net income to net cash flows provided by operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] 2029 Long-Term Debt, Maturity, Year Three Currently marketed products - products and product right Intangible Asset, Finite-Lived, Acquired Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Share-Based Payment Arrangement [Abstract] Cash Flows from Financing Activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Property, plant and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Schedule of Accrued and Other Current Liabilities Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Assets held for sale Assets held for sale Disposal Group, Including Discontinued Operation, Assets, Current Jada Jada [Member] Jada Stock Options, Awards (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Inventories valued under the LIFO method LIFO Inventory Amount Inventories Inventory Disclosure [Text Block] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Underlying Securities Award Underlying Securities Amount Intangible asset Intangible Asset, Excluding Goodwill, before Accumulated Amortization Financial Instruments Financial Instruments Disclosure [Text Block] Stock Options, Weighted Average Exercise Price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Inventories Increase (Decrease) in Inventories Gain on debt repurchase Gain (Loss) on Repurchase of Debt Instrument Cross Currency Interest Rate Contract, U.S. Dollar-Denominated Debt Instruments Cross Currency Interest Rate Contract, U.S. Dollar-Denominated Debt Instruments [Member] Cross Currency Interest Rate Contract, U.S. Dollar-Denominated Debt Instruments Europe and Canada Europe And Canada [Member] Europe And Canada Schedule of Maturities on Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Table] Debt instrument interest payments Debt Instrument, Interest Payments Debt Instrument, Interest Payments Equity Awards That are Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Other current assets Other Assets, Current Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Debt instruments gain (loss) Impact of net (gains) losses of derivative financial instruments Derivative, Gain (Loss) on Derivative, Net Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Current Fiscal Year End Date Current Fiscal Year End Date Gain on sale of Jada Gain on disposition of business Gain (Loss) on Disposition of Business Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Ganirelix Acetate Injection Ganirelix Acetate Injection [Member] Ganirelix Acetate Injection Emgality Emgality/Ravvow [Member] Emgality/Ravvow Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Common stock dividends declared (in dollars per share) Common Stock, Dividends, Per Share, Declared Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Weighted average exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Impairment of assets Asset, Impairment Loss Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock, issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Inventory Inventory Net And Inventory Noncurrent Inventory Net And Inventory Noncurrent Finished goods Inventory, Finished Goods, Gross Forward Contracts Forward Contracts [Member] Atozet Atozet [Member] Atozet Other expense (income), net Other Operating And Nonoperating Income (Expense) Other Operating And Nonoperating Income (Expense) Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Equity Components [Axis] Equity Components [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable Product and Service [Domain] Product and Service [Domain] Weighted average shares outstanding: Earnings Per Share, Diluted, Other Disclosure [Abstract] Proscar Proscar [Member] Proscar CALIFORNIA CALIFORNIA Schedule of Long-term Debt Instruments Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Entity Interactive Data Current Entity Interactive Data Current Supplies Other Inventory, Supplies, Gross Sebela Pharmaceutical Sebela Pharmaceutical [Member] Sebela Pharmaceutical Deferred income taxes Deferred Income Tax Liabilities, Net Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Entity Small Business Entity Small Business Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Termination Date Trading Arrangement Termination Date Trade accounts payable Increase (Decrease) in Accounts Payable, Trade Adjustment of fair value included in inventory Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Vytorin Vytorin [Member] Vytorin Document Type Document Type 5.125% notes due 2031 5.125% Senior Unsecured Notes Due 2031 [Member] 5.125% Senior Unsecured Notes Due 2031 Fair Value as of Grant Date Award Grant Date Fair Value Brazil BRAZIL Number of shareholder derivative lawsuits filed Number Of Shareholder Derivative Lawsuits Filed Number Of Shareholder Derivative Lawsuits Filed Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration Statement of Stockholders' Equity [Abstract] Proceeds from debt Proceeds from Issuance of Long-Term Debt Local Phone Number Local Phone Number Work in process Inventory, Work in Process, Gross Deferred taxes Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Euro Denominated Term Loan B Euro Denominated Senior Secured Tranche B Term Loan [Member] Euro Denominated Senior Secured Tranche B Term Loan Other comprehensive income (loss), pretax Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent Schedule of Equity Award Transactions Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block] Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Other assets Deferred Income Taxes and Other Assets, Noncurrent Stock Options, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Contingencies (Note 15) Commitments and Contingencies Revenues Sales Sales Revenues Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] China CHINA Counterparty Name [Axis] Counterparty Name [Axis] Liabilities and Equity Liabilities and Equity [Abstract] Gross profit sharing arrangement percentage Collaboration Arrangement, Profit Sharing Arrangement, Percentage Collaboration Arrangement, Profit Sharing Arrangement, Percentage Acquired in-process research and development and milestones Payments to Acquire in Process Research and Development Schedule of Financial Instruments Recorded at Estimated Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Inventories (excludes inventories of $273 in 2026 and $236 in 2025 classified in Other assets) Inventories Inventory, Net Award Type [Domain] Award Type [Domain] Euro Denominated Term Loan B Facility Euro Denominated Term Loan B Facility [Member] Euro Denominated Term Loan B Facility Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Level 3 Fair Value, Inputs, Level 3 [Member] 2034 Notes 2034 Notes [Member] 2034 Notes Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Expected life (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Stock Options, Remaining Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted-Average Remaining Contractual Term PEO Name PEO Name Geographical [Axis] Geographical [Axis] Accrued and other current liabilities Increase (Decrease) in Accrued Liabilities Ontruzant Ontruzant [Member] Ontruzant New Jersey State Court New Jersey State Court [Member] New Jersey State Court Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Contingent consideration discount rates Business Combination, Contingent Consideration, Liability, Measurement Input Schedule of Information Related to Collaboration Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Income tax benefits Share-Based Payment Arrangement, Expense, Tax Benefit Cash payments and other Payments for Restructuring Vested/Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Cash and Cash Equivalents, Beginning of Period Cash and Cash Equivalents, End of Period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Sun Pharma Sun Pharma [Member] Sun Pharma Rosuzet Rosuzet [Member] Rosuzet Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Debt Instrument [Axis] Debt Instrument [Axis] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Disposal Group Name [Axis] Disposal Group Name [Axis] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] 2027 Long-Term Debt, Maturity, Year One Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Basic (in dollars per share) Earnings Per Share, Basic Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Measurement Input Type [Axis] Measurement Input Type [Axis] Raw materials Inventory, Raw Materials, Gross Total Current Assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Schedule of (Gain) Loss on Derivative Instruments Derivative Instruments, Gain (Loss) [Table Text Block] Long-term debt Total Long-term debt, net of current portion Long-Term Debt, Excluding Current Maturities Award Type [Axis] Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accounts receivable (net of allowance for doubtful accounts of $13 in 2026 and $12 in 2025) Due from Merck in Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Retained earnings Retained Earnings (Accumulated Deficit) Euro-denominated debt instruments gain (loss) Euro-Denominated Debt Instrument [Member] Euro-Denominated Debt Instrument Restructuring and Related Activities [Abstract] Product and Service [Axis] Product and Service [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Stock [Member] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Accretion and changes in fair value in contingent consideration Business Combination, Contingent Consideration, Change in Contingent Consideration, Asset, Increase (Decrease) Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Int’l Non-US [Member] Organon Finance 1 LLC Organon Finance 1 LLC [Member] Organon Finance 1 LLC Derivative Contract [Domain] Derivative Contract [Domain] Equity Awards Adjustments Equity Awards Adjustments [Member] Noncurrent assets held for sale Noncurrent assets held for sale Disposal Group, Including Discontinued Operation, Assets, Noncurrent Samsung Collaboration Collaborative Arrangement Disclosure [Text Block] Asset Acquisition [Line Items] Asset Acquisition [Line Items] Total Liabilities and Stockholders’ Equity Liabilities and Equity Employee Stock Option Share-Based Payment Arrangement, Option [Member] Current portion of long-term debt and short-term borrowings Less: Current portion of long-term debt and short-term borrowings Debt, Current Notes Payable, Other Payables Notes Payable, Other Payables [Member] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Related Party [Domain] Related and Nonrelated Parties [Domain] Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Restructuring costs Restructuring Charges Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Revenue Interest Purchase and Sale Agreement Revenue Interest Purchase and Sale Agreement [Member] Revenue Interest Purchase and Sale Agreement Tabular List, Table Tabular List [Table Text Block] Femur Fracture Litigation Femur Fracture Litigation [Member] Femur Fracture Litigation Purchase of product rights and asset acquisition Payments to Acquire Intangible Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Other Non-Opiod Pain, Bone and Dermatology Other Non-Opiod Pain, Bone and Dermatology [Member] Other Non-Opiod Pain, Bone and Dermatology Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Restricted stock, Awards (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Number Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Outstanding, Number Forfeited/Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Federal Court Federal Court [Member] Federal Court Business Combination, Contingent Consideration, Type [Domain] Business Combination, Contingent Consideration, Type [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Number of pending claims Loss Contingency, Pending Claims, Number Equity Awards Vested and Expected to Vest Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest [Abstract] Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest Other Other Countries [Member] Other Countries Legal Entity of Counterparty, Type [Axis] Legal Entity of Counterparty, Type [Axis] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Loss contingency, number of plaintiffs to decline settlement offer Loss Contingency, Number Of Plaintiffs To Decline Settlement Offer Loss Contingency, Number Of Plaintiffs To Decline Settlement Offer Payments to acquire productive assets Payments to Acquire Productive Assets Statement of Cash Flows [Abstract] Euro-Denominated Subsidiaries Euro-Denominated Subsidiaries [Member] Euro-Denominated Subsidiaries Foreign Exchange Forward Foreign Exchange Forward [Member] Accrued and other current liabilities Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current Inventory [Line Items] Inventory [Line Items] Dulera Dulera [Member] Dulera Restructuring Restructuring and Related Activities Disclosure [Text Block] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Stock Options, Awards (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Name Measure Name Cross Currency Interest Rate Contract, Euro-Denominated Debt Instruments Cross Currency Interest Rate Contract, Euro-Denominated Debt Instruments [Member] Cross Currency Interest Rate Contract, Euro-Denominated Debt Instruments Headcount reductions, percent Restructuring and Related Cost, Number of Positions Eliminated, Inception to Date Percent Taxes on Income Income Tax Disclosure [Text Block] Trade accounts payable Payables to Samsung included in Trade accounts payable Due to Merck in Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Other Other Noncash Income (Expense) Debt Instrument [Line Items] Debt Instrument [Line Items] Other current assets Increase (Decrease) in Other Current Assets Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Payables in relation to license agreement, second installment Collaborative Arrangement, Rights and Obligations, Second Installment Payment Collaborative Arrangement, Rights and Obligations, Second Installment Payment Consideration transferred Business Combination, Consideration Transferred Additional Paid-In Capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Mylan Pharmaceuticals, Inc. Mylan Pharmaceuticals, Inc. (Mylan) [Member] Mylan Pharmaceuticals, Inc. (Mylan) Other Respiratory Other Respiratory [Member] Other Respiratory Name Trading Arrangement, Individual Name Cash and cash equivalents Cash and Cash Equivalent Encube Ethical Private Limited Encube Ethical Private Limited [Member] Encube Ethical Private Limited Basis of Presentation Basis of Accounting [Text Block] Company Selected Measure Amount Company Selected Measure Amount Total (approximates current cost) Inventory, Gross Stock Options, Remaining Term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term 6.750% secured notes due 2034 6.750% Senior Secured Notes Due 2034 [Member] 6.750% Senior Secured Notes Due 2034 Stock-based compensation plans and other (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Price in cash (in dollar per share) Business Combination, Price Per Share Current Assets: Assets, Current [Abstract] Nexplanon/Implanon NXT Nexplanon/Implanon NXT [Member] Nexplanon/Implanon NXT Non-PEO NEO Non-PEO NEO [Member] Senior Notes Senior Notes [Member] Zetia Zetia [Member] Zetia Entity Address, Address Line One Entity Address, Address Line One Vested/Exercised (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Income tax expense Income Tax Expense (Benefit) Exchange losses (gains) Gain (Loss), Foreign Currency Transaction, before Tax Stock-based compensation plans and other (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture and Adjustments Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture and Adjustments Arcoxia Arcoxia [Member] Arcoxia Cost of sales Cost of sales Cost of sales Cost of Product and Service Sold Award Timing Method Award Timing Method [Text Block] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Net Increase (Decrease) in Cash and Cash Equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Bildyos/Bilprevda Bildvos/Bilprevda [Member] Bildvos/Bilprevda Research and development Research and Development Expense (Excluding Acquired in Process Cost) Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Net income Net income Net income Net income Net Income (Loss) Attributable to Parent Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Statement [Table] Statement [Table] NuvaRing NuvaRing [Member] NuvaRing Renflexis Renflexis [Member] Renflexis Restatement Determination Date: Restatement Determination Date [Axis] Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Share-based Compensation Plans Share-Based Payment Arrangement [Member] Unrealized foreign exchange (gain) loss Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair value hedge liabilities Fair Value Hedge Liabilities Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract]